About
Enhanced T cell engagement and cytotoxic activity of blinatumomab in Mera
Enable safer, faster translation of human-relevant therapies by making predictive 3D organoid models the industry standard for preclinical testing.
Mera, a flow-based human tissue model, improves prediction of immunotherapy response by capturing dynamic immune-tumour interactions. Using clinically relevant conditions, the platform enables real-time assessment of efficacy and safety, avoiding key limitations of static in vitro systems.
Key findings
>2x
B-cell killing
Highly significant reduction under flow (p<0.001). No significant difference in static conditions (~1.1-fold).
1.7x
LDH release
Increase under flow vs. no-flow. LDH is a well-established marker of immune-mediated cytotoxicity.
~2x
IFN-y and IL-2
Elevation in key T cell activation cytokines. Most pronounced indicators of immune effector function.
4h
Detection window
Increased B-cell killing detected within 4 hours, indicating efficient T cell engagement.
What is in the download?
The full application note includes:
- Experimental methodology and study design
- Flow cytometry and LDH assay data
- Cytokine release profiles (TNF-a, IFN-y, IL-2)
- Static vs. Mera flow condition comparison
- CRS detection implications and framework
- Future outlook: patient-derived samples and personalised assessment
About
About the study
Blinatumomab is a bispecific T cell engager (BiTE) designed to simultaneously bind CD3 on T cells and CD19 on B cells, bridging cytotoxic T lymphocytes with malignant B cells to trigger targeted cell killing. Because this mechanism depends entirely on efficient cell-cell interaction and dynamic immune engagement, it is highly sensitive to the conditions in which it is tested - making it an ideal model system for demonstrating the impact of physiological flow on immunotherapy performance in Mera.
Interested in running a similar study for your therapeutic?
Our scientists can walk you through how Mera can be applied to your specific indication.